T TN ANTIGEN VACCINE IS EFFECTIVE AND SAFE IN PREVENTING RECURRENCE OF ADVANCED HUMAN BREAST-CARCINOMA/

For nearly 20 yrs, we use T/Tn antigen vaccine in safe, specific, effe ctive, long-term intradermal vaccination against recurrence of advance d breast carcinoma. Treatment is ad infinitum. All 18 breast carcinoma patients treated, pTNM Stages IV (6), III (6), survived >5 yrs postop eratively; 10 survived > 10 to > 18 yrs; of the latter, three patients each are Stages III and IV. Five additional 5 yr survivors have not y et reached 10 yrs. The probability that our survival results are due t o chance, with NCI ''1991 Standard PDQ Data'' as control, for all thre e stages taken together is: 5-yr survival: p<1 x 10(-8); 10-yr surviva l: p<1 x 10(-5). There were no untoward side effects. The vaccination area presented as a delayed-type hypersensitivity reaction, but at var iance with the PPD reaction, with significant inflammation, increase o f helper T lymphocytes and decrease of the T suppressor/cytotoxic cell ratio.